ASX Share rice
Sat 08 Aug 2020 - 07:27:pm (Sydney)

SPL Share Price

STARPHARMA HOLDINGS LIMITEDSPLPharmaceuticals, Biotechnology & Life Sciences

SPL Company Information

Name:

Starpharma Holdings Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

4-6 Southampton Crescent Abbotsford VIC Australia 3067

Phone:

61 3 8532 2700

CEO, MD & Exec. Director:

Dr. Jacinth K. Fairley M.B.A., B.Sc., B.V.Sc.(Hons), MBA, GAICD

CFO & Company Sec.:

Mr. Nigel J. Baade B.Com, Grad. Dip., CPA

Company Overview:

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1/2 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

SPL Share Price Information

Shares Issued:

372.54M

Market Capitalisation:

$404.21M

Revenue (TTM):

$7.73M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.04

Profit Margin:

-1.6625

Operating Margin (TTM):

$-1.66

Return On Assets (TTM):

$-0.16

Return On Equity (TTM):

$-0.30

Quarterly Revenue Growth (YOY):

7.579

Gross Profit(TTM):

$2.47M

Diluted Earnings Per Share (TTM):

$-0.036

SPL CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-306,000

Change To Liabilities:

$1.16M

Total Cashflow From Investing Activities:

$-306,000

Net Borrowings:

$-26,000

Net Income:

$-14,254,000

Total Cash From Operating Activities:

$-10,344,000

Depreciation:

$298K

Change To Inventory:

$-399,000

Change To Account Receivables:

$-23,000

Capital Expenditures:

$314K

SPL Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-14,254,000

Net Income:

$-14,254,000

Gross Profit:

$1.40M

Operating Income:

$-15,323,000

Total Revenue:

$1.65M

Total Operating Expenses:

$16.72M

Cost Of Revenue:

$251K

SPL Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$6.46M

Total Stockholder Equity:

$42.40M

Other Current Liabilities:

$1.25M

Total Assets:

$48.86M

Common Stock:

$193.62M

Retained Earnings:

$-168,001,000

Other Liabilities:

$38K

Cash:

$41.25M

Total Current Liabilities:

$6.43M

Property - Plant & Equipment:

$1.05M

Net Tangible Assets:

$42.40M

Total Current Assets:

$47.81M

Net Receivables:

$5.86M

Short-Term Investments:

$1.05M

Inventory:

$399K

Accounts Payable:

$4.10M

Non Currrent Assets (Other):

$1.05M

Short-Term Investments:

$1.05

Non Current Liabilities Total:

$38K

SPL Share Price History

SPL News

28 Jul, 2020
A look at the shareholders of Starpharma Holdings Limited (ASX:SPL) can tell us which group is most powerful...
29 Jun, 2020
NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.
23 Jun, 2020
NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.
22 Jun, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 18th conference are now available for on-demand viewing at VirtualInvestorConferences.com.
15 Jun, 2020
Virtual Investor Conferences today announced the agenda for the upcoming Global Virtual lnvestor Conference, the leading proprietary investor conference series. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET on Thursday, June 18th with the first live webcast at 10:30 AM ET
05 May, 2020
Jackie Fairley has been the CEO of Starpharma Holdings Limited (ASX:SPL) since 2006. This analysis aims first to...
16 Apr, 2020
Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-2 (coronavirus), which causes COVID-19
19 Mar, 2020
The last three months have been tough on Starpharma Holdings Limited (ASX:SPL) shareholders, who have seen the share...
31 Jan, 2020
Starpharma Holdings Limited's (ASX:SPL): Starpharma Holdings Limited engages in the research, development, and...
29 Dec, 2019
Starpharma: Commencement of phase 1 trial for AZD0466 utilising DEP® delivery technology
17 Dec, 2019
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
17 Oct, 2019
In 2006 Jackie Fairley was appointed CEO of Starpharma Holdings Limited (ASX:SPL). This report will, first, examine...
06 Sep, 2019
While Starpharma Holdings Limited (ASX:SPL) shareholders are probably generally happy, the stock hasn't had...